A retrospective study of characteristics and treatment outcomes of patients with DLBCL treated with the CAR T-cell therapies tisa-cel or axi-cel in US
Latest Information Update: 04 Feb 2022
Price :
$35 *
At a glance
- Drugs Axicabtagene ciloleucel (Primary) ; Tisagenlecleucel (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Therapeutic Use
- 14 Dec 2021 Results (n=88) presented at the 63rd American Society of Hematology Annual Meeting and Exposition.
- 04 Aug 2021 New trial record
- 17 Jun 2021 Results presented at the 26th Congress of the European Haematology Association